恩格列净治疗早期2型糖尿病肾病患者的临床疗效  

Clinical Efficacy on Empagliflozin in the Treatment of Patients with Early Type 2 Diabetic Nephropathy

作　　者：解合兰[1] 孙丹丹 杨明明[1] XIE He-Lan;SUN Dan-Dan;YANG Ming-Ming(Deparlment of Endocrinology,Heze Municiple Hospital,Heze 274000,China)

机构地区：[1]菏泽市立医院内分泌科,山东菏泽274000

出　　处：《中国药物经济学》2020年第6期86-89,共4页China Journal of Pharmaceutical Economics

摘　　要：目的探讨恩格列净对早期2型糖尿病肾病(DKD)的治疗效果,并探讨可能机制。方法选取2018年6—12月菏泽市立医院收治的60例早期2型DKD患者按随机数字表法分为两组,各30例,对照组单独采用胰岛素治疗,观察组给予恩格列净联合胰岛素。比较两组患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA1c)、体重、体重指数(BMI)、收缩压(SBP)、舒张压(DBP)、胆固醇(TC)、三酰甘油(TG)、尿酸(UA)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、尿白蛋白与肌酐比值(UACR)变化。结果治疗后,两组FBG、2hPBG、HbA1c显著下降,差异有统计学意义(P<0.05),但两组FBG、2hPBG、HbA1c比较,差异无统计学意义(P>0.05);治疗后,观察组BMI、体重、SBP、DBP显著低于对照组,差异有统计学意义(P<0.05);治疗后,观察组TG、TC、UACR、UA、IL-6、TNF-α显著低于对照组,差异有统计学意义(P<0.05)。结论恩格列净可有效降低早期2型DKD患者尿白蛋白,其机制可能与改善慢性炎症状态有关。Objective To explore the therapeutic effects of Empagliflozin on early diabetic nephropathy(DKD) and its possible mechanism. Methods From June to December 2018, a total of 60 patients with DKD in Heze Municiple Hospital were randomly divided into 2 groups(n=30). The control group was treated with insulin alone, while the observation group was treated with Empagliflozin and insulin. The changes of fasting blood glucose(FBG), 2 hours postprandial blood glucose(2 hPBG), glycosylated hemoglobin(HbA1 c), weight and body mass index(BMI), systolic blood pressure(SBP), diastolic blood pressure(DBP), cholesterol(TC), triglyceride(TG), uric acid(UA), IL-6, TNF-α and urinary albumin/creatinine ratio(UACR)were compared before and after treatment in the 2 groups. Results After treatment, FBG, 2 hBG and HbA1 c decreased significantly in both groups, and the difference was statistically significant(P<0.05);after treatment, the BMI, weight, SBP and DBP of the observation group were significantly lower than those of the control group, and the difference was statistically significant(P<0.05);after treatment, TG, TC, UACR, UA, IL-6, TNF-α in the observation group were significantly lower than those in the control group, and the difference was statistically significant(P<0.05). Conclusion Empagliflozin can effectively reduce urinary albumin in patients with early type 2 diabetic nephropathy, and its mechanism may be related to the improvement of chronic inflammatory state.

关 键 词：恩格列净 2型糖尿病 糖尿病肾病 尿微量白蛋白与肌酐比值 

分 类 号：R587.2[医药卫生—内分泌] R977.1[医药卫生—内科学]